Supply Chain/Logistics

The World Vaccine & Immunotherapy Congress West Coast is part of an award-winning series of conferences and exhibitions that are continuously growing becoming the largest and most established vaccine meetings of its kind across the globe. Scientific Affairs • Immunotherapy • Influenza • Infectious Disease • R&D • Regulatory Affairs • Manufacturing • Immunology • Oncology • Vaccines • Clinical Development • Partnerships

The Scientific Program features a diverse range of scientific sessions organized into two concurrent themed tracks covering issues such as Novel In Vitro and In Silico Assays to Predict Human Safety, In Vivo and Ex vivo Case Studies For Safety, Debate on the “Value” of Primary Tissue and In Vivo Studies and are disease Models Relevant in Safety Pharmacology, Macro Molecules Science: Antibodies, Oligo, and Peptides, Translation Beyond FIH Exposure Response Models, Macro Molecules Science: Gene therapy, Cell Therapy, mRNA and PROTAC, Derisking and Risk Mitigation Strategies, Clinical Cardiology, and much more! This will ensure attendees can stay abreast of new content and developments in key areas of interest. 

With more than 6,500 toxicologists from all over the world expected to attend, opportunities for networking and finding new collaborators are abundant—from the Scientific Sessions and other daytime events through the evening receptions. Research organizations, government agencies, drug developers, regulatory authorities, academic institutions, laboratory and medical suppliers, or consultants are encouraged to exhibit at ToxExpo.

RAPS Convergence is the largest and most well-recognized annual gathering of regulatory professionals, scientists, and innovators in the world. Convergence brings together representatives from industry, global regulatory bodies, and research, academic and clinical organizations that are directly involved in managing the regulatory process and aligning science, regulation, and business strategy.

The Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced in the pre-clinical stages and in clinical development. This includes challenges faces with drug targets including wet AMD, dry AMD, DME, IRDs and more.

The 2022 ISPE Annual Meeting & Expo will usher in a revitalized focus on excellence, modernization, and harmonization in pharmaceutical science and manufacturing across the globe, offering pharma professionals the opportunity to engage in industry-critical conversations. A comprehensive education program provides attendees with technical sessions on the latest developments in supply chain, operations, facilities, equipment, information systems, product development, production systems, quality systems, regulatory guidance and cutting-edge industry innovations. This signature event draws pharmaceutical and biopharmaceutical professionals at all levels of the industry from emerging leaders to the most senior executives in drug manufacturing, supply chain, devices and equipment and services, and global regulatory agencies. The conference Partner Showcase presents a large offering of the latest technologies and services for the pharmaceutical industry.

DCAT Week is not a Trade Show. It is a multifaceted event where DCAT Member Companies have the opportunity to reserve meeting space through the DCAT organization to conduct high-level, private, strategic meetings with customers and suppliers.

Returning in 2022, the Tumor Myeloid-Directed Therapeutics Summit is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment.  This is your ultimate forum to identify, validate, and clinically progress myeloid targets to expand the oncologists toolkit and realize better responses by engaging myeloid anti-tumor function. Designed for experts working directly on myeloid-directed therapies, and those in adjacent immuno-oncology fields, from cell therapy to checkpoint and engager development. If you’re scratching your head in attempt to enhance efficacy in solid tumors and overcome barriers in the microenvironment, this is your 500-foot view of the intricate pathways, interactions, and novel target development in the tumor microenvironment. Deep-dive into myeloid biology, guided by 27+ industry Gurus from the likes of Pionyr Immunotherapeutics, Gilead Sciences, Merck, Verseau Therapeutics, Carisma Therapeutics, Pfizer and many more. With targets such as TREM1 and TREM2 making waves in the clinic, analysis of CD47 candidates back-translating to next-generation therapies, and novel dendritic cell candidates such as FTL3 in development, this 3-day myeloid extravaganza is unmissable for anyone looking to unlock better therapeutic potential through the myeloid compartment.

As Biopharma turn their focus to autoimmune drug development, there has been an explosion of interest and investment into Treg directed therapies. Promising proof-of-concept data and early clinical read outs have fueled further hype, and the industry now looks to demonstrate efficacy. The 4th Treg Directed Therapies Summit returns to Boston this May, bigger and better than ever before, boasting 2 tracks of unparalleled content to cater to cell-based, and non-cell-based experts alike. This is the only industry-focused meeting designed to bridge the gap between early discovery through clinical development of cell-based and non cell-based Treg directed therapies to provide efficacious treatments for patients globally. With 3 days of unrivalled content spanning the fundamental biology of Tregs, optimizing early drug development, and streamlining clinical development, join with your team to:Optimize stable expansion of Tregs to maintain function to elicit durable responses
Decode Treg interactions to optimize the mechanism of actions and inform biomarker development
Rationalize activation, formulation & delivery strategy to induce antigen specific tolerance
Supercharge CMC strategy to drive the modulation of antigen-specific responses to yield maximum clinical efficacy